Abstract
The clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated proteins (Cas) system has significant potential in biological diagnostics because of its precise nucleic acid identification abilities. Traditional CRISPR diagnostics, however, have limitations such as insufficient signal output, dependence on exogenous enzymes, and high equipment demands. Nanozymes, as nanomaterials with enzyme-mimetic catalytic activity, integrate the catalytic efficiency of natural enzymes with the stability and modifiability of nanomaterials, providing a viable resolution to the limitations in CRISPR diagnostics. This article comprehensively evaluates the advancements in nanozyme-enhanced CRISPR diagnostic technologies. Furthermore, it delineates the fundamental attributes of the CRISPR diagnostic system and nanozymes, as well as the necessity of their integration. Moreover, the coupling mechanisms between the CRISPR/Cas system and nanozymes, including the regulation of nanozyme catalytic activity by Cas protein function and CRISPR signal amplification facilitated by nanozymes, were also comprehensively evaluated. The application of this technique in detecting nucleic acid and non-nucleic acid targets was assessed. Further, this study discusses the current limitations of this technology, such as complex separation of heterogeneous systems, laborious reaction protocols, and slow detection rates. The future advancements, such as the establishment of homogenous systems, the creation of integrated devices, and the utilization of single-atom nanozymes, have also been discussed in this review. The results of this study will provide references for the comprehensive integration of nanozymes and CRISPR technology, together with their diagnostic applications.
1 Introduction
Biological diagnostic technology is fundamental in areas such as disease prevention and control, food safety monitoring, and environmental quality evaluation, where sensitivity, specificity, and detection efficiency remain focal points of research (Kaminski et al., 2021). Despite their high sensitivity, traditional diagnostic methods like Polymerase Chain Reaction (PCR) depend on complex temperature-controlled instruments, experienced workers, or prolonged amplification durations, complicating the achievement of on-site rapid detection (Yang and Rothman, 2004; Niemz et al., 2011; Chowdhry et al., 2023). In recent years, the CRISPR/Cas system has become a core tool for next-generation diagnostic technology due to its programmable nucleic acid recognition capability and collateral cleavage activity activated by targets, enabling the development of representative diagnostic platforms such as SHERLOCK and DETECTR (Gootenberg et al., 2017; Chen et al., 2018; Chen et al., 2022; Kaminski et al., 2021; Soh et al., 2022; Li H. et al., 2023). However, the CRISPR/Cas system has intrinsic limitations: firstly, the signal output generally relies on the cleavage of fluorescent probes, which necessitates specialized fluorescence detection apparatus, increasing the cost and operational complexity (Kellner et al., 2019; Fozouni et al., 2021; Kaminski et al., 2021). Secondly, certain systems require the addition of natural enzymes in the signal reporting stage, such as horseradish peroxidase (HRP), but these enzymes are susceptible to inactivation and demand stringent storage conditions, elevating detection costs and operational complexity (Gao et al., 2007; Wei and Wang, 2013; Zhang et al., 2021; Babaei et al., 2025).
The identification of nanozymes has introduced a novel method for addressing the aforementioned issues. After the discovery of peroxidase-like activity in Fe3O4 nanoparticles in 2007, nanozymes have been significantly used in biosensing, attributed to their excellent catalytic stability, cost-effectiveness, scalability in synthesis, and easy surface functionalization (Gao et al., 2007; Huang et al., 2019; Jiang et al., 2019; Liang and Yan, 2019; Shamsabadi et al., 2024). Currently synthesized nanozymes include various catalytic forms, such as peroxidases, oxidases, and nucleases, as well as different material systems such as CeO2, MnO2, MoS2, and noble-metal-based nanostructures (Huang et al., 2019; Tian et al., 2025). The integration of nanozymes with the CRISPR/Cas system facilitates the effective amplification of CRISPR recognition signals via the catalytic properties of nanozymes, simplifying the detection process and allowing for visual and cost-effective detection by utilizing the characteristics of nanomaterials (Wu et al., 2022; Arshad et al., 2024). Wu et al. (2022) devised a MnO2 nanozyme-mediated CRISPR-Cas12a system that enables colorimetric detection of SARS-CoV-2 by modulating the catalytic activity of MnO2 nanozymes via cleavage following Cas12a activation, avoiding the need for a sophisticated detection apparatus (Wu et al., 2022).
In recent years, nanozyme-enhanced CRISPR diagnostic technology has attained significant advancements in target detection range and efficacy (Broto et al., 2022; Shamsabadi et al., 2024). It has evolved from the original detection of nucleic acids to encompass non-nucleic acid targets, including tiny compounds, proteins, and heavy metal ions. The detection sensitivity has been increased to the aM level, and on-site detection modalities, including smartphone help, have been implemented (Chen et al., 2024; Deng et al., 2024; Zhang et al., 2024; Che et al., 2025). This article focuses on “why nanozymes + CRISPR” and systematically investigates the coupling mechanisms, application scenarios, and research advancements of nanozymes and CRISPR, while addressing existing controversies and prospective development trajectories, offering references for further investigation in this domain.
2 Coupling mechanism
The effective integration of the CRISPR/Cas system with nanozymes is essential for efficient diagnostics. This process involves modulating the catalytic activity of nanozymes through target recognition by the CRISPR/Cas system, amplifying the recognition signal of the CRISPR/Cas system by leveraging the catalytic properties of nanozymes, and improving detection efficacy through the synergistic assembly of nanozymes and CRISPR.
2.1 Regulation of nanozyme catalytic function by Cas protein activity
The primary purpose of the CRISPR/Cas system is to identify target nucleic acids via crRNA and to initiate the nucleic acid cleavage activity of Cas proteins, which includes both the precise cleavage of target nucleic acids and the collateral cleavage activity of non-specific reporter molecules (Kaminski et al., 2021). The Cas12a protein can non-specifically cleave single-stranded DNA (ssDNA) (Chen et al., 2018). Using this attribute, ssDNA can be altered on the surface of nanozymes to function as a “molecular switch.” After target recognition, CRISPR/Cas12a cleaves ssDNA on nanozymes’ surfaces, altering their surface charge, dispersibility, or active-site exposure and thus modulating their catalytic activity (Liu et al., 2015; Zeng et al., 2019). For instance, the MnO2 nanozyme-mediated CRISPR/Cas12a colorimetric approach delineated by Wu et al. (2022), wherein the activation of Cas12a triggers the cleavage of ssDNA affixed to the MnO2 nanozyme surface, reactivating the nanozyme-catalyzed chromogenic reaction for the detection of SARS-CoV-2 (Wu et al., 2022). Furthermore, Tao et al. (2025) showed a MoS2 quantum-dot system in which Cas12a-regulated DNA cleavage on MoS2 QDs alters the enzyme-mimicking properties, facilitating sensitive colorimetric detection of viral DNA targets (Tao et al., 2025). Collectively, these examples highlight a common design logic: CRISPR/Cas trans-cleavage acts as the “gate” that rewires nanozyme surface chemistry into a measurable catalytic signal, providing a compact and modular coupling strategy.
2.2 Multi-level amplification of CRISPR signals mediated by nanozymes
The improved catalytic activity of nanozymes allows multi-tier amplification of the CRISPR/Cas system recognition signal, addressing the issue of limited signal intensity in the conventional CRISPR/Cas system (Broto et al., 2022; Shamsabadi et al., 2024). This process generally combines CRISPR-mediated target identification with the catalytic activity of nanozymes, creating a sequential “recognition-cleavage-catalytic amplification” response (Babaei et al., 2025). In a standard design framework, crRNA recognition initiates Cas trans-cleavage to cleave various nucleic-acid linkers, releasing numerous nanozymes. Each nanozyme catalyzes multiple substrate molecules to provide enhanced optical or electrochemical outputs (Chen et al., 2023; Xu et al., 2023; Luo et al., 2024).
For example, Zhang et al. (2023) created a nanozyme-mediated amplification-free CRISPR system. It employs the collateral cleavage activity initiated by Cas12a following target recognition to cleave the DNA linker that connects nanozymes to magnetic beads, releasing the nanozymes from the magnetic bead surface. The released nanozymes facilitate the chromogenic process. A single Cas12a can cleave numerous DNA linkers to release multiple nanozymes, with each nanozyme capable of catalyzing several substrate molecules. This results in multi-level signal amplification, enabling the visual detection of target nucleic acids without the need for nucleic acid amplification steps, reducing the detection time to 30 min (Zhang et al., 2023). Mechanistically, this coupling mode emphasizes reporter multiplicity and catalytic turnover rather than solely changing the intrinsic activity of a single nanozyme particle.
2.3 Synergistic assembly of nanozymes and CRISPR to improve detection performance
Beyond activity gating and catalytic amplification, because of the assembly characteristics of nanomaterials, the CRISPR/Cas system and nanozymes can be systematically organized into functional complexes, which would increase their synergistic effect and strengthen the specificity and stability of detection (Liu S. et al., 2024; Sui et al., 2025; Zhang X. et al., 2025). In practice, this coupling mode often relies on programmable co-localization (e.g., DNA-guided assembly) or confined microenvironments (e.g., nanostructured scaffolds/nanoflowers) to increase effective local concentrations, suppress nonspecific interactions, and stabilize catalytic activity under challenging conditions.
Jiang et al. (2024) proposed a dCas9-mediated dual-signal platform that facilitates target-dependent assembly of Au–Pt nanozyme units, thus simultaneously amplifying catalytic and SERS responses, which enables high-specificity detection, including single-base discrimination (Jiang et al., 2024). Moreover, Qiu et al. (2024) developed a self-assembled bifunctional nanoflower-based CRISPR/Cas platform for dual-readout detection of Salmonella enterica, demonstrating that confined microenvironments and co-encapsulation can increase assay stability and efficacy in complex matrices (Qiu et al., 2024). Overall, this coupling mode highlights that assembly is not merely a packaging step. It can be a functional design lever that improves robustness, reduces interference, and supports integrated readouts, which is particularly relevant for practical deployment.
3 Nucleic acid target detection
Nucleic acid testing for pathogenic genomes and clinically significant biomarkers, including both DNA and RNA targets, remains the primary domain of CRISPR diagnostics (Kellner et al., 2019; Broughton et al., 2020). However, molecular diagnostics continues to face limitations, such as low target abundance, matrix-derived interference, and the necessity for rapid, instrument-light readouts appropriate for dispersed testing (Emaus et al., 2020; Budd et al., 2023; Chakraborty, 2024). The incorporation of nanozymes has significantly improved the sensitivity, speed, and on-site application of detection through high-turnover catalytic signal transduction and resilient nano-interfaces (Zandieh and Liu, 2021; Zhao et al., 2023; Wang et al., 2024).
3.1 DNA target detection
DNA-target detection includes bacterial genomic markers, viral sequences, and clinically significant biomarkers (Niemz et al., 2011; Kellner et al., 2019; Broughton et al., 2020). Nanozyme-mediated CRISPR assays are particularly beneficial in this field. Collateral-cleavage CRISPR nucleases, such as Cas12a and Cas14a, convert sequence recognition into collateral cleavage, whereas nanozymes transform these molecular events into enhanced colorimetric, electrochemical, or electrochemiluminescent (ECL) outputs (Chen et al., 2018; Harrington et al., 2018; Huang et al., 2019; Li C. et al., 2023; Arshad et al., 2024).
Li et al. (2023) presented a CRISPR Cas14a electrochemical biosensor, employing PtPd@PCN-224 nanozymes as catalytic signal tags to enhance the hydrogen peroxide reduction current, demonstrating a characteristic electrochemical format that promotes catalytic signal amplification (Figure 1A). In the presence of target DNA, activated Cas14a initiates trans-cleavage of phosphorylated ssDNA at the electrode interface, inhibiting the assembly of PtPd@PCN-224 on the electrode through Zr-O-P coordination and resulting in a signal-off reduction in current, thus facilitating ultrasensitive detection of pathogenic bacterial DNA (Li C. et al., 2023).
FIGURE 1
Arshad et al. (2024) proposed an electrochemical transduction approach by creating a CeO2 nanozyme-mediated RPA-CRISPR/Cas12a dual-mode biosensor targeting the invA gene of Salmonella (Figure 1B). This strategy involves the initial amplification of the invA sequence via RPA, which then activates the CRISPR/Cas12a-crRNA complex to cleave a FAM-quencher ssDNA reporter, producing a fluorescent signal for sequence-specific identification. The technology employs a CeO2 nanozyme-mediated colorimetric readout for orthogonal validation. The technology utilizes the inherent oxidase- and peroxidase-like properties of CeO2 in the presence of H2O2 to produce a target-dependent chromatic transition, providing reliable dual-signal confirmation. This assay attained a minimal detection threshold of 10 CFU/mL and exhibited strong anti-interference characteristics in complex food matrices, including milk and chicken (Arshad et al., 2024).
3.2 RNA target detection
RNA-target detection focuses on viral genomes and regulatory non-coding RNAs (Abudayyeh et al., 2016; Barnes et al., 2020; Yang and Patel, 2024). Relative to DNA targets, RNA analytes are generally rarer, more prone to degradation, and frequently considerably smaller, particularly miRNAs (Garneau et al., 2007; Dong et al., 2013; Jet et al., 2021). These attributes require robust signal transduction and efficient background suppression (Dong et al., 2013; Chen F. et al., 2022). For this, nanozymes provide high-turnover catalytic amplification and adaptable readout modalities, enhancing the programmability of CRISPR systems (Thamilselvan and Kim, 2024; Zhang L. et al., 2025).
Wu et al. (2022) presented a MnO2 nanozyme-assisted CRISPR/Cas12a platform for the fast detection of the SARS-CoV-2 ORF1ab gene in RNA viruses. The method initially transforms viral RNA templates into double-stranded DNA (dsDNA) intermediates by reverse transcription-recombinase polymerase amplification (RT-RPA). Subsequently, the Cas12a-crRNA complex selectively identifies this DNA, initiating trans-cleavage activity that cleaves ssDNA linkers modified on the surface of magnetic beads, therefore releasing the immobilized MnO2 into the supernatant. The released MnO2 facilitates TMB color formation through its peroxidase-like activity. This method produces visually discernible outcomes in 45 min, indicating great potential for point-of-care epidemiological surveillance (Wu et al., 2022).
In addition to infections, non-coding RNAs function as essential biomarkers in cancer, although their detection is complicated by their low quantity. Broto et al. (2022) devised the CrisprZyme approach, which combines Cas13/gRNA-mediated RNA detection with an NLISA-type colorimetric output facilitated by extremely efficient Pt@Au nanozymes (Figure 1C). This technique utilizes Cas13 and gRNA recognition to initiate collateral cleavage of a tagged reporter RNA, while the remaining intact reporter binds streptavidin-functionalized Pt@Au nanozymes via biotin contact, catalyzing the oxidation of a chromogenic substrate for quantitative analysis. The authors showed significant applicability across microRNAs, long non-coding RNAs, and circular RNAs in complex samples, including oncological tissue biopsy analysis utilizing circ-AURKA to differentiate between prostate cancer subtypes (Broto et al., 2022).
To improve sensitivity, Shen et al. (2022) integrated miRNA-initiated rolling circle amplification (RCA) with Cas12a trans-cleavage and a hybridization chain reaction circuit, introducing a nanozyme cascade readout that combines beta cyclodextrin-modified gold nanoparticles with an Fe-based MOF nanozyme NH2-MIL-88B to promote dual photoelectrochemical and colorimetric outputs (Figure 1D). This multi-amplification system attained sub-femtomolar analytical sensitivity, with detection limits of 0.3 fM for photoelectrochemistry and 0.5 fM for colorimetry, facilitating accurate miRNA differentiation in complex conditions (Shen et al., 2022).
Collectively, the above examples illustrate that nanozyme-assisted CRISPR nucleic-acid assays are evolving from proof-of-concept signal conversion toward designs that explicitly optimize matrix tolerance, detection confirmation, and operational convenience. Therefore, A new platforms can be guided by measurable engineering criteria, including time to result, number of manual handling steps, susceptibility to background in real matrices, and the degree to which the readout is quantitative and portable. This analysis helps clarify why specific architectures are selected for distinct nucleic-acid use cases.
4 Non-nucleic acid target detection
Conventional CRISPR/Cas systems primarily focus on nucleic acids. The incorporation of recognition elements such as aptamers has effectively enhanced nanozyme-mediated CRISPR/Cas systems to detect non-nucleic acid targets, including proteins, small compounds, and heavy metal ions, significantly improving the applicability of CRISPR diagnostic technology.
4.1 Protein detection
Protein biomarkers are essential for clinical screening and disease management; however, their detection by CRISPR systems is limited by the inability of the Cas-crRNA combination to directly recognize them (Tang et al., 2022; Hartl et al., 2023; Carrasco-Zanini et al., 2024). Therefore, the majority of CRISPR-based protein assays depend on an aptamer or antibody to transform a protein-binding event into the release or production of an activator DNA that can initiate the trans-cleavage of the CRISPR/Cas system (Li et al., 2021; Tang et al., 2022; Paialunga et al., 2025). The nanozyme component functions as the signal output and amplification module, converting CRISPR-mediated nucleic acid cleavage into a visual or electrochemical alteration (Mu et al., 2023).
Mu et al. (2023) established a visual biosensor for carcinoembryonic antigen (CEA) by integrating rolling circle amplification (RCA), CRISPR/Cas12a, and peroxidase-mimicking DNA–Ag/Pt nanoclusters (NCs) (Figure 2A). The design involves CEA binding to an aptamer complex, which releases a primer strand that promotes padlock probe circularization and initiates RCA, resulting in the production of long repetitive DNA products comprising Cas12a activator sequences; a subsequent nicking step increases the quantity of activator to activate Cas12a. The activated Cas12a subsequently cleaves the DNA scaffold on the Ag/Pt nanoclusters, thus inhibiting the peroxidase-mimetic activity and reducing the UV–vis signal. The assay, employing cascade amplification from RCA and CRISPR, achieved a linear range of 2.5 pg/mL to 2.0 ng/mL, with a detection limit of 0.94 pg/mL, and was verified with serum samples.
FIGURE 2
4.2 Small molecule detection
The identification of small compounds, including mycotoxins, metabolites, and medication residues, is crucial for guaranteeing food safety and enhancing clinical monitoring (Li et al., 2018). Nanozyme-assisted CRISPR platforms address the inherent limitations of small-molecule detection, such as low molecular weight and the absence of multiple binding epitopes, by combining aptamer-based affinity ligands with the trans-cleavage functionality of Cas proteins, converting small-molecule binding events into substantial signals (Niu et al., 2021; Li et al., 2022; Zhu and Zhao, 2023; Liu M. et al., 2024; Zhu et al., 2025).
Wu et al. (2024) integrated a nanozyme–CRISPR cascade into an electrochemical, centrifugal microfluidic system for the detection of ochratoxin A (OTA). Pd@PCN-222 nanozyme catalyzes the reduction of H2O2, producing a reduction current. In the presence of OTA, competitive binding between OTA and the aptamer strand releases cDNA, which subsequently binds to crRNA and activates Cas12a trans-cleavage; the activated Cas12a then cleaves ssDNA connecting Pd@PCN-222 and the electrode, resulting in a reduction of Pd@PCN-222 at the electrode interface and decreasing the H2O2 reduction peak current, facilitating preamplification-free detection with a reported detection limit of 1.21 pg mL−1. The on-chip incubation and trans-cleavage processes were programmable, allowing on-site workflow integration (Wu et al., 2024).
Esmaelpourfarkhani et al. (2024) established a CRISPR-Cas12a colorimetric aptasensor for the detection of Aflatoxin M1 (AFM1) in a complementary solution-based colorimetric format by manipulating the quasi-oxidase activity of flower-like MnO2 nanozymes through a CRISPR/Cas12a system (Figure 2B). In the absence of AFM1, CRISPR/Cas12a is activated and randomly cleaves the ssDNA, restoring the elevated oxidase-like activity of the MnO2 nanoflowers and generating a pronounced absorbance signal due to enhanced TMB oxidation. In the presence of AFM1, the CRISPR/Cas12a module remains inactive, resulting in the retention of ssDNA on the nanozyme surface, which inhibits nanozyme activity, restricting TMB oxidation and yielding a low absorbance. The detection limit is as low as 0.05 ng/mL, and the detection outcomes in milk samples correspond with those obtained using high-performance liquid chromatography (Esmaelpourfarkhani et al., 2024).
4.3 Heavy metal ion detection
Heavy metal ions (e.g., Pb2+ and Hg2+) are persistent, non-degradable contaminants that can bioaccumulate and demonstrate significant toxicity at low concentrations, resulting in multi-organ damage. Therefore, there is an urgent need to develop rapid and sensitive detection technologies (Balali-Mood et al., 2021; Pan et al., 2024; Yang et al., 2025). To address the restricted signal transduction and vulnerability to background interference frequently observed in ion-triggered experiments, the integration of the CRISPR/Cas system with a nanozyme readout system improves the amplification of catalytic signals (Xu et al., 2023; Meng et al., 2025).
Xu et al. (2023) developed a DNAzyme-activated, MnO2 nanozyme-mediated CRISPR/Cas12a colorimetric protocol for the detection of Pb2+ without preamplification (Figure 2C). Pb2+ is specifically identified by the GR-5 DNAzyme, which cleaves it at the “rA” site, resulting in the release of a short trigger DNA (tDNA) that subsequently activates the CRISPR/Cas12a system. Activated Cas12a cleaves the ssDNA linker connecting MnO2 nanorods to magnetic beads (ssDNA-MnO2-MBs), resulting in the cleavage of MnO2 and a reduced TMB oxidation signal. The assay demonstrated a linear range of 0.8–2,500 nM, with a stated limit of detection (LOD) of 0.54 nM. Furthermore, specificity can be improved by dual recognition, but sensitivity is increased by MnO2 serving as a stable catalytic signal probe that amplifies color output without target preamplification.
Overall, extending nanozyme-assisted CRISPR diagnostic technology to non-nucleic acid targets shifts the central challenge toward reliable molecular transduction. Future platform development is likely to benefit from transducer designs that minimize background, and tolerate complex sample matrices, as well as integrated devices that reduce manual steps while preserving the catalytic gain of nanozyme reporters.
5 Conclusion and future
Nanozyme-assisted CRISPR diagnostic technology has transformed biological diagnostics by integrating the complementary advantages of CRISPR/Cas-mediated molecular recognition with nanozyme-facilitated signal amplification, resulting in an integrated “recognition-amplification-readout” framework. This integration provides numerous substantial benefits. First, it facilitates visibility and reduces equipment requirements, as nanozymes transform CRISPR signals into recognizable colorimetric or simple electrochemical outputs, which eliminates the need for complex fluorescence-based equipment. Secondly, it achieves significant sensitivity, with detection limits generally approaching the femtomolar to attomolar range, substantially surpassing traditional CRISPR assays. Moreover, the integration of nanozymes provides increased stability, thus facilitating prolonged storage at ambient temperature. The integration of components such as aptamers extends the technology’s application range, allowing comprehensive detection of both nucleic acid and non-nucleic acid targets.
Despite this potential, the extensive application of nanozyme-assisted CRISPR platforms is restricted by various limitations. A primary issue is the nanozyme’s limited substrate specificity, which can increase background noise and compromise quantitative precision. Moreover, the prevalence of diverse test formats, commonly utilizing magnetic bead-based support, necessitates labor-intensive washing and separation procedures. These restrictions prolong the turnaround time and increase procedure complexity, which are unfavorable to point-of-care testing (POCT). Furthermore, complex biological matrices may undermine analytical accuracy: endogenous redox-active compounds and nonspecific protein adsorption might disrupt the CRISPR/Cas system and nanozyme functionality, resulting in inaccurate responses.
Future advancements in nanozyme-assisted CRISPR diagnostics will largely depend on overcoming various obstacles. At the catalyst level, increasing nanozyme activity and catalytic selectivity via site-isolated or single-atom engineering and customized surface functionalization will be crucial for mitigating nonspecific background interference and enhancing quantitative dependability. Transitioning from bead- or carrier-dependent heterogeneous workflows to homogeneous, separation-free architectures in assay format could significantly improve operations and reduce time-to-result, as demonstrated by target-triggered nanozyme assembly/disassembly or proximity-regulated catalytic switching. Furthermore, matrix robustness is essential for real-sample analysis, as endogenous redox-active species and nonspecific adsorption can disrupt either CRISPR/Cas activity or nanozyme catalysis; therefore, antifouling interfaces, matrix-tolerant buffers, and internal controls must be integrated to mitigate inaccurate responses. The integration of molecular and materials advancements with device engineering and standardized validation will ultimately determine the potential of nanozyme-assisted CRISPR platforms to evolve into widely applicable point-of-care testing solutions in clinical diagnostics, food safety, and environmental monitoring.
Statements
Author contributions
LL: Writing – original draft, Writing – review and editing, Investigation, Visualization. YY: Formal Analysis, Investigation, Writing – review and editing. YZ: Methodology, Project administration, Writing – review and editing, Writing – original draft. GM: Funding acquisition, Supervision, Writing – review and editing, Conceptualization, Project administration.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the National Key Research and Development Program of China (2025YFF1207700), the Guangdong Provincial Key Laboratory of Synthetic Genomics (2023B1212060054), and Shenzhen Key Laboratory of Synthetic Genomics (ZDSYS201802061806209).
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AbudayyehO. O.GootenbergJ. S.KonermannS.JoungJ.SlaymakerI. M.CoxD. B. T.et al (2016). C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science353, aaf5573. 10.1126/science.aaf5573
2
ArshadF.AbdillahA.ShivanandP.AhmedM. (2024). CeO2 nanozyme mediated RPA/CRISPR-Cas12a dual-mode biosensor for detection of invA gene in salmonella. Biosens. Bioelectron.247, 115940. 10.1016/j.bios.2023.115940
3
BabaeiE.SmailS. W.BalakyS. T. J.HadiN. M.AzeezH. J. (2025). Nanozyme-assisted CRISPR/cas systems as an emerging platform for food safety applications: recent advances. Microchem. J.212, 113270. 10.1016/j.microc.2025.113270
4
Balali-MoodM.NaseriK.TahergorabiZ.KhazdairM. R.SadeghiM. (2021). Toxic mechanisms of five heavy metals: mercury, lead, chromium, cadmium, and arsenic. Front. Pharmacol.12, 643972. 10.3389/fphar.2021.643972
5
BarnesK. G.LachenauerA. E.NitidoA.SiddiquiS.GrossR.BeitzelB.et al (2020). Deployable CRISPR-Cas13a diagnostic tools to detect and report ebola and lassa virus cases in real-time. Nat. Commun.11, 4131. 10.1038/s41467-020-17994-9
6
BrotoM.KaminskiM. M.AdrianusC.KimN.GreensmithR.Dissanayake-PereraS.et al (2022). Nanozyme-catalysed CRISPR assay for preamplification-free detection of non-coding RNAs. Nat. Nanotechnol.17, 1120–1126. 10.1038/s41565-022-01179-0
7
BroughtonJ. P.DengX.YuG.FaschingC. L.ServellitaV.SinghJ.et al (2020). CRISPR–Cas12-based detection of SARS-CoV-2. Nat. Biotechnol.38, 870–874. 10.1038/s41587-020-0513-4
8
BuddJ.MillerB. S.WeckmanN. E.CherkaouiD.HuangD.DecruzA. T.et al (2023). Lateral flow test engineering and lessons learned from COVID-19. Nat. Rev. Bioeng.1, 13–31. 10.1038/s44222-022-00007-3
9
Carrasco-ZaniniJ.PietznerM.DavitteJ.SurendranP.Croteau-ChonkaD. C.RobinsC.et al (2024). Proteomic signatures improve risk prediction for common and rare diseases. Nat. Med.30, 2489–2498. 10.1038/s41591-024-03142-z
10
ChakrabortyS. (2024). Democratizing nucleic acid-based molecular diagnostic tests for infectious diseases at resource-limited settings – from point of care to extreme point of care. Sens. Diagn3, 536–561. 10.1039/D3SD00304C
11
CheR.TangD.FuB.WenT.WangZ.FengD.et al (2025). Smartphone-integrated tri-mode RCA-CRISPR/Cas12a biosensor with Fe3O4@Au nanozyme for on-site detection of sugarcane smut at attomolar level. Biosens. Bioelectron.290, 117985. 10.1016/j.bios.2025.117985
12
ChenJ. S.MaE.HarringtonL. B.Da CostaM.TianX.PalefskyJ. M.et al (2018). CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science360, 436–439. 10.1126/science.aar6245
13
ChenF.LiG.WuC.WangL.KoC.-N.MaD.-L.et al (2022). Interference reduction biosensing strategy for highly sensitive microRNA detection. Anal. Chem.94, 4513–4521. 10.1021/acs.analchem.2c00138
14
ChenY.XuX.WangJ.ZhangY.ZengW.LiuY.et al (2022). Photoactivatable CRISPR/Cas12a strategy for one-pot DETECTR molecular diagnosis. Anal. Chem.94, 9638–9645. 10.1021/acs.analchem.2c01193
15
ChenM.CopleyS. J.ViolaP.LuH.AboagyeE. O. (2023). Radiomics and artificial intelligence for precision medicine in lung cancer treatment. Semin. Cancer Biol.93, 97–113. 10.1016/j.semcancer.2023.05.004
16
ChenW.LiuP.SunX.XiongB.CuiH.ZhaoZ.et al (2024). Spatioselective occlusion of copolymer nanoparticles within calcite crystals generates organic-inorganic hybrid materials with controlled internal structures. Angew. Chem. Int. Ed.63, e202410908. 10.1002/anie.202410908
17
ChowdhryR.LuS.LeeS.GodhulayyagariS.EbrahimiS.SamantaD. (2023). Enhancing CRISPR/cas systems with nanotechnology. Trends Biotechnol.41, 1549–1564. 10.1016/j.tibtech.2023.06.005
18
DengF.LiY.YangB.SangR.DengW.KansaraM.et al (2024). Topological barrier to Cas12a activation by circular DNA nanostructures facilitates autocatalysis and transforms DNA/RNA sensing. Nat. Commun.15, 1818. 10.1038/s41467-024-46001-8
19
DongH.LeiJ.DingL.WenY.JuH.ZhangX. (2013). MicroRNA: function, detection, and bioanalysis. Chem. Rev.113, 6207–6233. 10.1021/cr300362f
20
EmausM. N.VaronaM.EitzmannD. R.HsiehS.-A.ZegerV. R.AndersonJ. L. (2020). Nucleic acid extraction: fundamentals of sample preparation methodologies, current advancements, and future endeavors. TrAC Trends Anal. Chem.130, 115985. 10.1016/j.trac.2020.115985
21
EsmaelpourfarkhaniM.RamezaniM.AlibolandiM.AbnousK.TaghdisiS. (2024). CRISPR-Cas12a-based colorimetric aptasensor for aflatoxin M1 detection based on oxidase-mimicking activity of flower-like MnO2 nanozymes. Talanta271, 125729. 10.1016/j.talanta.2024.125729
22
FozouniP.SonS.DerbyM. D. de L.KnottG. J.GrayC. N.D’AmbrosioM. V.et al (2021). Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy. Cell184, 323–333.e9. 10.1016/j.cell.2020.12.001
23
GaoL.ZhuangJ.NieL.ZhangJ.ZhangY.GuN.et al (2007). Intrinsic peroxidase-like activity of ferromagnetic nanoparticles. Nat. Nanotechnol.2, 577–583. 10.1038/nnano.2007.260
24
GarneauN. L.WiluszJ.WiluszC. J. (2007). The highways and byways of mRNA decay. Nat. Rev. Mol. Cell Biol.8, 113–126. 10.1038/nrm2104
25
GootenbergJ. S.AbudayyehO. O.LeeJ. W.EssletzbichlerP.DyA. J.JoungJ.et al (2017). Nucleic acid detection with CRISPR-Cas13a/C2c2. Science356, 438–442. 10.1126/science.aam9321
26
HarringtonL.BursteinD.ChenJ.Paez-EspinoD.MaE.WitteI.et al (2018). Programmed DNA destruction by miniature CRISPR-Cas14 enzymes. Science362, 839–842. 10.1126/science.aav4294
27
HartlJ.KurthF.KappertK.HorstD.MüllederM.HartmannG.et al (2023). Quantitative protein biomarker panels: a path to improved clinical practice through proteomics. EMBO Mol. Med.15, e16061. 10.15252/emmm.202216061
28
HuangY.RenJ.QuX. (2019). Nanozymes: classification, catalytic mechanisms, activity regulation, and applications. Chem. Rev.119, 4357–4412. 10.1021/acs.chemrev.8b00672
29
JetT.GinesG.RondelezY.TalyV. (2021). Advances in multiplexed techniques for the detection and quantification of microRNAs. Chem. Soc. Rev.50, 4141–4161. 10.1039/D0CS00609B
30
JiangD.NiD.RosenkransZ. T.HuangP.YanX.CaiW. (2019). Nanozyme: new horizons for responsive biomedical applications. Chem. Soc. Rev.48, 3683–3704. 10.1039/C8CS00718G
31
JiangH.ChangW.ZhuX.LiuG.LiuK.ChenW.et al (2024). Development of a colorimetric and SERS dual-signal platform dCas9-mediated chain assembly of bifunctional Au@Pt nanozymes for ultrasensitive and robust salmonella assay. Anal. Chem.96, 12684–12691. 10.1021/acs.analchem.4c01474
32
KaminskiM. M.AbudayyehO. O.GootenbergJ. S.ZhangF.CollinsJ. J. (2021). CRISPR-based diagnostics. Nat. Biomed. Eng.5, 643–656. 10.1038/s41551-021-00760-7
33
KellnerM. J.KoobJ. G.GootenbergJ. S.AbudayyehO. O.ZhangF. (2019). SHERLOCK: nucleic acid detection with CRISPR nucleases. Nat. Protoc.14, 2986–3012. 10.1038/s41596-019-0210-2
34
LiY.ZhangG.MaoX.YangS.De RuyckK.WuY. (2018). High sensitivity immunoassays for small molecule compounds detection – novel noncompetitive immunoassay designs. TrAC Trends Anal. Chem.103, 198–208. 10.1016/j.trac.2018.04.008
35
LiY.MansourH.WatsonC. J. F.TangY.MacNeilA. J.LiF. (2021). Amplified detection of nucleic acids and proteins using an isothermal proximity CRISPR Cas12a assay. Chem. Sci.12, 2133–2137. 10.1039/D0SC06113A
36
LiX.ChenX.MaoM.PengC.WangZ. (2022). Accelerated CRISPR/Cas12a-based small molecule detection using bivalent aptamer. Biosens. Bioelectron.217, 114725. 10.1016/j.bios.2022.114725
37
LiC.LiuC.LiuR.WangY.LiA.TianS.et al (2023). A novel CRISPR/Cas14a-based electrochemical biosensor for ultrasensitive detection of burkholderia pseudomallei with PtPd@PCN-224 nanoenzymes for signal amplification. Biosens. Bioelectron.225, 115098. 10.1016/j.bios.2023.115098
38
LiH.KielichD.LiuG.SmithG.BelloA.StrongJ.et al (2023). Strategies to improve multi-enzyme compatibility and coordination in one-pot SHERLOCK. Anal. Chem.95, 10522–10531. 10.1021/acs.analchem.2c05032
39
LiangM.YanX. (2019). Nanozymes: from new concepts, mechanisms, and standards to applications. Acc. Chem. Res.52, 2190–2200. 10.1021/acs.accounts.9b00140
40
LiuB.SunZ.HuangP.-J. J.LiuJ. (2015). Hydrogen peroxide displacing DNA from nanoceria: mechanism and detection of glucose in serum. J. Am. Chem. Soc.137, 1290–1295. 10.1021/ja511444e
41
LiuM.LiX.ZhouS.MenD.DuanY.LiuH.et al (2024). Ultrasensitive detection of mycotoxins using a novel single-atom, CRISPR/Cas12a-based nanozymatic colorimetric biosensor. Chem. Eng. J.497, 154418. 10.1016/j.cej.2024.154418
42
LiuS.XuL.HuangZ.ZhangY.PeiX.LiS.et al (2024). Recent advances of nanoparticles-assisted CRISPR/cas biosensors. Microchem. J.199, 109930. 10.1016/j.microc.2024.109930
43
LuoB.ZhouJ.ZhanX.YingB.LanF.WuY. (2024). Visual and colorimetric detection of microRNA in clinical samples based on strand displacement amplification and nanozyme-mediated CRISPR-Cas12a system. Talanta277, 126310. 10.1016/j.talanta.2024.126310
44
MengX.YueY.HuangM.DuanZ.LiuK.WuL. (2025). DNAzyme-CRISPR driven dual-mode biosensor with nanozyme signal amplification for on-site Pb2+ detection. Anal. Chim. Acta1379, 344711. 10.1016/j.aca.2025.344711
45
MuX.LiJ.XiaoS.XuJ.HuangY.ZhaoS.et al (2023). Peroxidase-mimicking DNA-Ag/Pt nanoclusters mediated visual biosensor for CEA detection based on rolling circle amplification and CRISPR/cas 12a. Sens. Actuators B Chem.375, 132870. 10.1016/j.snb.2022.132870
46
NiemzA.FergusonT. M.BoyleD. S. (2011). Point-of-care nucleic acid testing for infectious diseases. Trends Biotechnol.29, 240–250. 10.1016/j.tibtech.2011.01.007
47
NiuC.WangC.LiF.ZhengX.XingX.ZhangC. (2021). Aptamer assisted CRISPR-Cas12a strategy for small molecule diagnostics. Biosens. Bioelectron.183, 113196. 10.1016/j.bios.2021.113196
48
PaialungaE.BagheriN.RossettiM.FabianiL.MicheliL.Chamorro-GarciaA.et al (2025). Leveraging synthetic antibody–DNA conjugates to expand the CRISPR-Cas12a biosensing toolbox. ACS Synth. Biol.14, 171–178. 10.1021/acssynbio.4c00541
49
PanZ.GongT.LiangP. (2024). Heavy metal exposure and cardiovascular disease. Circ. Res.134, 1160–1178. 10.1161/CIRCRESAHA.123.323617
50
QiuM.YuanZ.LiN.YangX.ZhangX.JiangY.et al (2024). Self-assembled bifunctional nanoflower-enabled CRISPR/Cas biosensing platform for dual-readout detection of Salmonella enterica. J. Hazard. Mater.471, 0–13. 10.1016/j.jhazmat.2024.134323
51
ShamsabadiA.HaghighiT.CarvalhoS.FrenetteL. C.StevensM. M. (2024). The nanozyme revolution: enhancing the performance of medical biosensing platforms. Adv. Mater.36, 2300184. 10.1002/adma.202300184
52
ShenH.YangH.QilengA.MaY.LiangH.MengJ.et al (2022). Programmable readout sensor for microRNA: CRISPR/Cas12a-assisted multi-amplification strategy activated photoelectrochemistry-colorimetry detection. Sens. Actuators B Chem.371, 132585. 10.1016/j.snb.2022.132585
53
SohJ. H.BallezaE.Abdul RahimM. N.ChanH.-M.Mohd AliS.ChuahJ. K. C.et al (2022). CRISPR-based systems for sensitive and rapid on-site COVID-19 diagnostics. Trends Biotechnol.40, 1346–1360. 10.1016/j.tibtech.2022.06.002
54
SuiZ.ChenB.ZhaoJ.YangH.GuoL.XuJ. (2025). Dual-accelerated signal amplification in biosensing via spatial confining catalytic hairpin assembly-activated spherical CRISPR/Cas12a system for trans-cleavage of hairpin DNA reporters. Anal. Chem.97, 4668–4677. 10.1021/acs.analchem.4c07111
55
TangY.SongT.GaoL.YinS.MaM.TanY.et al (2022). A CRISPR-based ultrasensitive assay detects attomolar concentrations of SARS-CoV-2 antibodies in clinical samples. Nat. Commun.13, 4667. 10.1038/s41467-022-32371-4
56
TaoY.WangH.JuE.LaoY.ZhangY.LiM. (2025). CRISPR-Cas12a-regulated DNA adsorption on MoS2 quantum dots: enhanced enzyme mimics for sensitive colorimetric detection of human monkeypox virus and human papillomavirus DNA. Talanta283, 127153. 10.1016/j.talanta.2024.127153
57
ThamilselvanA.KimM. I. (2024). Recent advances on nanozyme-based electrochemical biosensors for cancer biomarker detection. TrAC Trends Anal. Chem.177, 117815. 10.1016/j.trac.2024.117815
58
TianQ.LiS.TangZ.ZhangZ.DuD.ZhangX.et al (2025). Nanozyme-enabled biomedical diagnosis: advances, trends, and challenges. Adv. Healthc. Mater.14, 2401630. 10.1002/adhm.202401630
59
WangK.MengX.YanX.FanK. (2024). Nanozyme-based point-of-care testing: revolutionizing environmental pollutant detection with high efficiency and low cost. Nano Today54, 102145. 10.1016/j.nantod.2023.102145
60
WeiH.WangE. (2013). Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes. Chem. Soc. Rev.42, 6060–6093. 10.1039/c3cs35486e
61
WuL.WangX.WuX.XuS.LiuM.CaoX.et al (2022). MnO2 nanozyme-mediated CRISPR-Cas12a system for the detection of SARS-CoV-2. ACS Appl. Mater. Interfaces14, 50534–50542. 10.1021/acsami.2c14497
62
WuC.YueY.HuangB.JiH.WuL.HuangH. (2024). CRISPR-powered microfluidic biosensor for preamplification-free detection of ochratoxin a. Talanta269, 125414. 10.1016/j.talanta.2023.125414
63
XuS.WangS.GuoL.TongY.WuL.HuangX. (2023). Nanozyme-catalysed CRISPR-Cas12a system for the preamplification-free colorimetric detection of lead ion. Anal. Chim. Acta1243, 340827. 10.1016/j.aca.2023.340827
64
YangH.PatelD. J. (2024). Structures, mechanisms and applications of RNA-centric CRISPR–Cas13. Nat. Chem. Biol.20, 673–688. 10.1038/s41589-024-01593-6
65
YangS.RothmanR. E. (2004). PCR-based diagnostics for infectious diseases: uses, limitations, and future applications in acute-care settings. Lancet Infect. Dis.4, 337–348. 10.1016/S1473-3099(04)01044-8
66
YangY.QiH.HouX.GaoM.GongS. (2025). Recent advances (2019–2025) in Mercury ion detection. Crit. Rev. Anal. Chem., 1–17. 10.1080/10408347.2025.2511136
67
ZandiehM.LiuJ. (2021). Nanozyme catalytic turnover and self-limited reactions. ACS Nano15, 15645–15655. 10.1021/acsnano.1c07520
68
ZengC.LuN.WenY.LiuG.ZhangR.ZhangJ.et al (2019). Engineering nanozymes using DNA for catalytic regulation. ACS Appl. Mater. Interfaces11, 1790–1799. 10.1021/acsami.8b16075
69
ZhangR.YanX.FanK. (2021). Nanozymes inspired by natural enzymes. Acc. Mater. Res.2, 534–547. 10.1021/accountsmr.1c00074
70
ZhangX.GaoY.LiJ.YanJ.LiuP.FanX.et al (2023). A novel TAPP-DHTA COF cathodic photoelectrochemical immunosensor based on CRISPR/Cas12a-induced nanozyme catalytic generation of heterojunction. Electrochimica Acta441, 141771. 10.1016/j.electacta.2022.141771
71
ZhangY.YuW.WangM.ZhangL.LiP. (2024). Nanozyme-assisted amplification-free CRISPR/cas system realizes visual detection. Front. Bioeng. Biotechnol.11, 1327498. 10.3389/fbioe.2023.1327498
72
ZhangL.HeX.HuJ.BaiH.YaoY.HuW. (2025). Recent advances in nanozyme–CRISPR/cas biosensors. Chem. Commun.61, 19735–19749. 10.1039/D5CC05585G
73
ZhangX.ZhuL.YangL.ZhouY.LiH.GaoY.et al (2025). DNA triangular prism nanostructure and CRISPR/Cas12a empowered electrochemical biosensor for dual detection of alpha-fetoprotein and microRNA 122. Biosens. Bioelectron.287, 117697. 10.1016/j.bios.2025.117697
74
ZhaoZ.LuM.WangN.LiY.ZhaoL.ZhangQ.et al (2023). Nanomaterials-assisted CRISPR/Cas detection for food safety: advances, challenges and future prospects. TrAC Trends Anal. Chem.167, 117269. 10.1016/j.trac.2023.117269
75
ZhuF.ZhaoQ. (2023). CRISPR/Cas12a-powered competitive immunosorbent assay for small molecules. Anal. Chem.95, 14720–14726. 10.1021/acs.analchem.3c02834
76
ZhuZ.MaH.YaoH.YuanY.MiaoX.SuS. (2025). CRISPR-enhanced colorimetric aptasensor for adenosine triphosphate detection based on MoS2-based nanozymes. Biosensors15, 651. 10.3390/bios15100651
Summary
Keywords
biosensing, CRISPR diagnostics, nanozymes, point-of-care testing, signal amplification
Citation
Luo L, Yang Y, Zhang Y and Mao G (2026) Advances in nanozyme-assisted CRISPR diagnostic technology. Front. Bioeng. Biotechnol. 14:1796403. doi: 10.3389/fbioe.2026.1796403
Received
26 January 2026
Revised
07 February 2026
Accepted
19 February 2026
Published
26 February 2026
Volume
14 - 2026
Edited by
Garima Sharma, Kangwon National University, Republic of Korea
Reviewed by
Siyu Chen, Shenzhen Polytechnic, China
Updates
Copyright
© 2026 Luo, Yang, Zhang and Mao.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Guobin Mao, gb.mao@siat.ac.cn; Yubei Zhang, yb.zhang4@siat.ac.cn
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.